Natasha Kamal, MD
Gastroenterology · Frederick, MDNPI 1669748141
Payments from drug & device makers
What this record shows
This record is dominated by grants: $80,000 of the $131,090 with a category attached, or 61.0%. Pfizer accounts for 61.4% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $80,186 and has fallen 92.2% since, to $6,249 in 2025. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 380 payments — averaging $344.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$80K
- E.r. Squibb & Sons, L.L.C.$28K
- Johnson & Johnson$8K
- Phathom Pharmaceuticals, Inc.$4K
- Bristol Myers Squibb$3K
- Genentech USA, Inc.$2K
- plus $5K from 22 others
What the payments were for
- Consulting fees$10,3558%
- Speaking & faculty fees$24,84419%
- Grants$80,00061%
- Travel & lodging$6,6915%
- Food & beverage$9,1767%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 27 | $80,488 |
| E.r. Squibb & Sons, L.L.C. | 21 | $28,409 |
| Johnson & Johnson(2 entities) | 32 | $7,948 |
| Phathom Pharmaceuticals, Inc. | 9 | $3,851 |
| Bristol Myers Squibb | 44 | $2,820 |
| Genentech USA, Inc. | 5 | $2,216 |
| AbbVie | 98 | $2,202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $960 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 41 | $676 |
| Regeneron Healthcare Solutions, Inc. | 8 | $272 |
| Sanofi | 6 | $233 |
| Boston Scientific | 3 | $170 |
| Lilly USA, LLC | 7 | $147 |
| Intercept Pharmaceuticals, Inc. | 4 | $91 |
| Gilead | 3 | $87 |
| Ironwood Pharmaceuticals, Inc | 6 | $84 |
| Fresenius Kabi USA, LLC | 3 | $70 |
| Aimmune Therapeutics, Inc. | 2 | $53 |
| Ardelyx, Inc. | 2 | $50 |
| Nestle Healthcare Nutrition Inc. | 2 | $43 |
| Endo Pharmaceuticals Inc. | 3 | $43 |
| Braintree Laboratories, Inc. | 2 | $36 |
| Merck | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Celltrion USA Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$131,090 in reported general payments places this provider in the 95th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 35 | $893,129 |
| XifaxanRifaximin | 11 | $45,252 |
| LinzessLinaclotide | 31 | $41,672 |
| TrulancePlecanatide | 11 | $14,884 |
| Mesalamine | 19 | $9,613 |
| Colestipol Hcl | 44 | $4,395 |
| Pantoprazole Sodium | 222 | $4,392 |
| Dexlansoprazole DrDexlansoprazole | 22 | $4,302 |
| Ursodiol | 15 | $4,165 |
| Lubiprostone | 11 | $2,448 |
| Esomeprazole Magnesium | 15 | $1,485 |
| Omeprazole | 78 | $1,477 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 25 | $1,414 |
| Budesonide DrBudesonide | 12 | $1,147 |
| Dicyclomine Hcl | 25 | $1,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $7,948 | $893,12935 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $676 | $60,13722 claims |
| AbbVieLinzess | $2,202 | $41,67231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Frederick
- Dawei YangFrederick$31K
- Sanmeet SinghFrederick$20K
- Apurva ModiRockville$1.1M
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Zachary BormanChevy Chase$520K
- Mouen KhashabBaltimore$440K
- Erica CohenChevy Chase$385K
- Natarajan RavendhranCatonsville$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.